Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced Bladder cancer in 2020. CA Cancer J Clin. 2020;70(5):404–23.

Article  PubMed  Google Scholar 

Advanced Bladder Cancer Overview Collaboration. Neoadjuvant chemotherapy for invasive Bladder cancer. Cochrane Database Syst Rev. 2005;2004(2):CD005246.

Google Scholar 

Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced Bladder cancer. N Engl J Med. 2003;349(9):859–66.

Article  CAS  PubMed  Google Scholar 

International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive Bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol off J Am Soc Clin Oncol. 2011;29(16):2171–7.

Article  Google Scholar 

Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol off J Am Soc Clin Oncol. 2014;32(18):1889–94.

Article  CAS  Google Scholar 

Koga F, Yoshida S, Kawakami S, Kageyama Y, Yokoyama M, Saito K, et al. Low-dose chemoradiotherapy followed by partial or radical cystectomy against muscle-invasive Bladder cancer: an intent-to-treat survival analysis. Urology. 2008;72(2):384–8.

Article  PubMed  Google Scholar 

Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Vavassori I, Barni S. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in Bladder cancer treated with cystectomy: a meta-analysis. Eur Urol. 2014;65(2):350–7.

Article  Google Scholar 

Kundra V, Silverman PM. Imaging in oncology from the University of Texas M. D. Anderson Cancer Center. Imaging in the diagnosis, staging, and follow-up of cancer of the urinary bladder. AJR Am J Roentgenol. 2003;180(4):1045–54.

Article  PubMed  Google Scholar 

Choi SJ, Park KJ, Lee G, Kim MH, Kim JK. Urothelial phase CT for assessment of pathologic complete response after neoadjuvant chemotherapy in muscle-invasive Bladder cancer. Eur J Radiol. 2020;126:108902.

Article  PubMed  Google Scholar 

Woo S, Panebianco V, Narumi Y, Del Giudice F, Muglia VF, Takeuchi M, et al. Diagnostic performance of Vesical Imaging Reporting and Data System for the prediction of muscle-invasive Bladder Cancer: a systematic review and Meta-analysis. Eur Urol Oncol. 2020;3(3):306–15.

Article  PubMed  PubMed Central  Google Scholar 

Del Giudice F, Flammia RS, Pecoraro M, Moschini M, D’Andrea D, Messina E, et al. The accuracy of Vesical Imaging-Reporting and Data System (VI-RADS): an updated comprehensive multi-institutional, multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations. World J Urol. 2022;40(7):1617–28.

Article  PubMed  PubMed Central  Google Scholar 

Woo S, Suh CH, Kim SY, Cho JY, Kim SH, Moon MH. Head-to-head comparison between Biparametric and multiparametric MRI for the diagnosis of Prostate Cancer: a systematic review and Meta-analysis. AJR Am J Roentgenol. 2018;211(5):W226–41.

Article  PubMed  Google Scholar 

Bricio TGM, Gouvea GL, Barros RV, Chahud F, Elias J, Reis RB, et al. What is the impact of dynamic contrast-enhancement sequence in the Vesical Imaging, Reporting and Data System (VI-RADS)? A subgroup analysis. Cancer Imaging off Publ Int Cancer Imaging Soc. 2022;22(1):20.

Google Scholar 

Manganaro L, Anastasi E, Porpora MG, Vinci V, Saldari M, Bernardo S, et al. Biparametric Magnetic Resonance Imaging as an Adjunct to CA125 and HE4 to improve characterization of large ovarian masses. Anticancer Res. 2015;35(11):6341–51.

CAS  PubMed  Google Scholar 

Woo S, Ghafoor S, Das JP, Gangai N, Goh AC, Vargas HA. Plasmacytoid urothelial carcinoma of the bladder: MRI features and their association with survival. Urol Oncol. 2022;40(3):108e1–10.

Article  Google Scholar 

Das JP, Woo S, Ghafoor S, Andrieu PIC, Ulaner GA, Donahue TF, et al. Value of MRI in evaluating urachal carcinoma: a single center retrospective study. Urol Oncol Semin Orig Investig. 2022;40(7):345e9–17.

Google Scholar 

Necchi A, Bandini M, Calareso G, Raggi D, Pederzoli F, Farè E, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in muscle-invasive Bladder Cancer: preliminary findings from the PURE-01 study. Eur Urol. 2020;77(5):636–43.

Article  CAS  PubMed  Google Scholar 

Wang Hjun, Pui MH, Guo Y, Yang D, Pan B, tao. Zhou X Hui. Diffusion-weighted MRI in bladder carcinoma: the differentiation between Tumor recurrence and benign changes after resection. Abdom Imaging. 2014;39(1):135–41.

Article  PubMed  Google Scholar 

Yoshida S, Koga F, Kawakami S, Ishii C, Tanaka H, Numao N, et al. Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive Bladder cancer. Urology. 2010;75(2):387–91.

Article  PubMed  Google Scholar 

Donaldson SB, Bonington SC, Kershaw LE, Cowan R, Lyons J, Elliott T, et al. Dynamic contrast-enhanced MRI in patients with muscle-invasive transitional cell carcinoma of the bladder can distinguish between residual tumour and post-chemotherapy effect. Eur J Radiol. 2013;82(12):2161–8.

Article  PubMed  Google Scholar 

Wibmer AG, Nikolovski I, Chaim J, Lakhman Y, Lefkowitz RA, Sala E, et al. Local extent of Prostate Cancer at MRI versus Prostatectomy Histopathology: associations with Long-term oncologic outcomes. Radiology. 2022;302(3):595–602.

Article  PubMed  Google Scholar 

Iyer G, Balar AV, Milowsky MI, Bochner BH, Dalbagni G, Donat SM, et al. Multicenter prospective phase II trial of Neoadjuvant dose-dense Gemcitabine Plus Cisplatin in patients with muscle-invasive Bladder Cancer. J Clin Oncol off J Am Soc Clin Oncol. 2018;36(19):1949–56.

Article  CAS  Google Scholar 

Woo S, Kim SY, Cho JY, Kim SH. Preoperative evaluation of Prostate Cancer aggressiveness: using ADC and ADC ratio in determining Gleason Score. AJR Am J Roentgenol. 2016;207(1):114–20.

Article  PubMed  Google Scholar 

Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Diagnostic performance of DWI for differentiating high- from low-Grade Clear Cell Renal Cell Carcinoma: a systematic review and Meta-analysis. AJR Am J Roentgenol. 2017;209(6):W374–81.

Article  PubMed  Google Scholar 

Ahmed SA, Taher MGA, Ali WA, Ebrahem MAES. Diagnostic performance of contrast-enhanced dynamic and diffusion-weighted MR imaging in the assessment of Tumor response to neoadjuvant therapy in muscle-invasive Bladder cancer. Abdom Radiol N Y. 2021;46(6):2712–21.

Article  Google Scholar 

Bandini M, Calareso G, Raggi D, Marandino L, Colecchia M, Gallina A, et al. The Value of Multiparametric Magnetic Resonance Imaging Sequences to assist in the decision making of muscle-invasive Bladder Cancer. Eur Urol Oncol. 2021;4(5):829–33.

Article  PubMed  Google Scholar 

Aslan S, Cakir IM, Oguz U, Bekci T, Demirelli E. Comparison of the diagnostic accuracy and validity of biparametric MRI and multiparametric MRI-based VI-RADS scoring in Bladder cancer; is contrast material really necessary in detecting muscle invasion? Abdom Radiol N Y. 2022;47(2):771–80.

Article  Google Scholar 

Thompson HM, Bates DDB, Pernicka JG, Park SJ, Nourbakhsh M, Fuqua JL et al. MRI Assessment of Extramural Venous Invasion before and after total neoadjuvant therapy for locally advanced rectal Cancer and its Association with Disease-Free and overall survival. Ann Surg Oncol. 2023.

Pecoraro M, Del Giudice F, Magliocca F, Simone G, Flammia S, Leonardo C, et al. Vesical Imaging-Reporting and Data System (VI-RADS) for assessment of response to systemic therapy for Bladder cancer: preliminary report. Abdom Radiol N Y. 2022;47(2):763–70.

Article  Google Scholar 

Wu J, Xie RY, Cao CZ, Shang BQ, Shi HZ, Shou JZ. Disease Management of Clinical Complete Responders to Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer: A Review of Literature. Front Oncol [Internet]. 2022 [cited 2023 May 4];12. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043546/.

Iyer G, Ballman KV, Atherton PJ, Murray K, Kwok Y, Steen PD, et al. A phase II study of gemcitabine plus cisplatin chemotherapy in patients with muscle-invasive Bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations (Alliance A031701). J Clin Oncol. 2022;40(16suppl):TPS4615–5.

Article  Google Scholar 

Hafeez S, Koh M, Jones K, Ghzal AE, D’Arcy J, Kumar P, et al. Diffusion-weighted MRI to determine response and long-term clinical outcomes in muscle-invasive Bladder cancer following neoadjuvant chemotherapy. Front Oncol. 2022;12:961393.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chakiba C, Cornelis F, Descat E, Gross-Goupil M, Sargos P, Roubaud G, et al. Dynamic contrast enhanced MRI-derived parameters are potential biomarkers of therapeutic response in bladder carcinoma. Eur J Radiol. 2015;84(6):1023–8.

Article  PubMed  Google Scholar 

Del Giudice F, Pecoraro M, Vargas HA, Cipollari S, De Berardinis E, Bicchetti M, et al. Systematic review and Meta-analysis of Vesical Imaging-Reporting and Data System (VI-RADS) Inter-observer Reliability: an added value for muscle invasive Bladder Cancer detection. Cancers. 2020;12(10):2994.

Article  PubMed  PubMed Central  Google Scholar